Topos Bio

Research updates, model releases and technical write-ups from Topos Bio.

The company publishes a technical report on Topos-1, its foundation model for intrinsically disordered proteins.

The company introduces Topos-2, its next-generation model for generating conformational ensembles across the order-disorder spectrum, and previews Topos-Bind, a generative model for conformational ensembles of disordered proteins bound to small molecules.

Press releases, announcements and media coverage from Topos Bio.

Topos Bio is pioneering a new frontier in drug discovery by targeting Intrinsically Disordered Proteins (IDPs).

Redefining Druggable Space - Targeting Intrinsically Disordered Proteins

Topos Bio has launched two AI foundation models designed to predict protein-based therapies for diseases previously considered 'undruggable'. The company leverages artificial intelligence to identify potential treatment pathways where traditional drug development has failed. This approach targets conditions that lack effective pharmaceutical interventions due to their biological complexity.

Oct 2026GamesBeatNews article

Dalriada Drug Discovery partners with Topos Bio to accelerate drug discovery for intrinsically disordered proteins (IDPs). The collaboration leverages advanced protein mass spectrometry and proteomics to validate experimental targets. Dalriada specializes in small-molecule drug development, while Topos focuses on AI-driven therapeutics for IDPs.

Mar 2026PR NewswireNews article

Topos Bio raises **$10.5 million** to develop therapies targeting previously undruggable proteins. Oasys secures **$4.6 million** to advance digital mental health solutions. Both companies focus on high-need areas in drug discovery and behavioral care.

Jan 2026Healthcare IT TodayNews article

Topos Bio secures $10.5 million in seed funding to develop drugs targeting intrinsically disordered proteins, a previously inaccessible class linked to Alzheimer’s and cancer. The round includes Boldstart, Threshold, Neo, and angel investors like Dara Khosrowshahi and Naveen Rao. This financing supports the company’s novel drug discovery platform aimed at these ‘undruggable’ targets.

Jan 2026HLTHNews article